Showing results (141-150 of 277) with videos related to

Sort By:
Pageof 28
Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.
British Journal of Clinical Pharmacology|August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumoursDarcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
Nature Medicine|June 28, 2011
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNeil Johnson, Yu-Chen Li, Zandra E Walton, et al.
Cancer Discovery|April 25, 2019
PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast CancerConstantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Cancer|April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumorsMeghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid TumorsSuzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.
The New England Journal of Medicine|February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated TumorsEcaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Pageof 28